Home
/
Tvardi Therapeutics, Inc.
/
Financials
/
Quarterly
Tvardi Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Tvardi Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2017
Sep 30, 2017
$911.0K
Nov 2, 2017
Q2
2017
Jun 30, 2017
$911.0K
Aug 3, 2017
Q1
2018
Mar 31, 2017
$911.0K
May 9, 2018
Q3
2017
Sep 30, 2016
$86.0K
Nov 2, 2017
Q2
2017
Jun 30, 2016
$79.0K
Aug 3, 2017
Q1
2017
Mar 31, 2016
$7.0K
May 4, 2017
Q3
2016
Sep 30, 2015
$2.44M
Nov 4, 2016
Q2
2016
Jun 30, 2015
$874.0K
Aug 4, 2016
Q1
2016
Mar 31, 2015
$489.0K
May 5, 2016
Q3
2015
Sep 30, 2014
$1.13M
Nov 9, 2015
Q2
2015
Jun 30, 2014
$960.0K
Aug 10, 2015
Q1
2015
Mar 31, 2014
$178.0K
May 12, 2015
Q3
2014
Sep 30, 2013
$1.02M
Nov 10, 2014
Q2
2014
Jun 30, 2013
$9.97M
Aug 7, 2014
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2025
Mar 31, 2025
$2.57M
May 13, 2025
Q3
2024
Sep 30, 2024
$2.56M
Nov 14, 2024
Q2
2024
Jun 30, 2024
$991.0K
Aug 14, 2024
Q1
2025
Mar 31, 2024
$2.14M
May 13, 2025
Q3
2024
Sep 30, 2023
$4.87M
Nov 14, 2024
Q2
2024
Jun 30, 2023
$6.93M
Aug 14, 2024
Q1
2024
Mar 31, 2023
$6.17M
May 13, 2024
Q3
2023
Sep 30, 2022
$10.81M
Nov 13, 2023
Q2
2023
Jun 30, 2022
$23.00M
Aug 7, 2023
Q1
2023
Mar 31, 2022
$4.79M
May 15, 2023
Q3
2022
Sep 30, 2021
$20.27M
Nov 7, 2022
Q2
2022
Jun 30, 2021
$1.94M
Aug 8, 2022
Q1
2022
Mar 31, 2021
$1.94M
May 9, 2022
Q3
2021
Sep 30, 2020
$9.27M
Nov 8, 2021
Q2
2021
Jun 30, 2020
$5.63M
Aug 9, 2021
Q1
2021
Mar 31, 2020
$8.09M
May 10, 2021
Q3
2020
Sep 30, 2019
$5.79M
Nov 9, 2020
Q2
2020
Jun 30, 2019
$5.21M
Aug 10, 2020
Q1
2020
Mar 31, 2019
$4.38M
May 11, 2020
Q3
2019
Sep 30, 2018
$5.06M
Nov 5, 2019
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($5.53M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
$4.17M
Aug 14, 2025
Q3
2025
Jun 30, 2025
$4.17M
Nov 13, 2025
Q1
2025
Mar 31, 2025
($4.91M)
May 13, 2025
Q2
2025
Mar 31, 2025
($9.58M)
Aug 14, 2025
Q3
2025
Mar 31, 2025
($9.58M)
Nov 13, 2025
Q3
2025
Sep 30, 2024
($5.51M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($6.98M)
Aug 14, 2025
Q3
2025
Jun 30, 2024
($6.98M)
Nov 13, 2025
Q3
2025
Mar 31, 2024
($4.20M)
Nov 13, 2025
Q2
2025
Mar 31, 2024
($4.20M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($30.70M)
May 13, 2025
Q3
2024
Sep 30, 2023
($28.03M)
Nov 14, 2024
Q3
2024
Jun 30, 2023
($31.48M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($31.48M)
Aug 14, 2024
Q2
2024
Mar 31, 2023
($26.67M)
Aug 14, 2024
Q3
2024
Mar 31, 2023
($26.67M)
Nov 14, 2024
Q1
2024
Mar 31, 2023
($26.67M)
May 13, 2024
Q3
2023
Sep 30, 2022
($23.18M)
Nov 13, 2023
Q3
2023
Jun 30, 2022
($4.21M)
Nov 13, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($5.94M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($8.87M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($2.39M)
May 13, 2025
Q3
2025
Sep 30, 2024
($5.68M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($7.18M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($29.67M)
May 13, 2025
Q3
2024
Sep 30, 2023
($28.90M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($32.34M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($27.65M)
May 13, 2024
Q3
2023
Sep 30, 2022
($23.85M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($4.47M)
Aug 7, 2023
Q1
2023
Mar 31, 2022
($27.91M)
May 15, 2023
Q3
2022
Sep 30, 2021
($1.12M)
Nov 7, 2022
Q2
2022
Jun 30, 2021
($30.88M)
Aug 8, 2022
Q1
2022
Mar 31, 2021
($23.56M)
May 9, 2022
Q3
2021
Sep 30, 2020
($17.02M)
Nov 8, 2021
Q2
2021
Jun 30, 2020
($25.88M)
Aug 9, 2021
Q1
2021
Mar 31, 2020
($30.00M)
May 10, 2021
Q3
2020
Sep 30, 2019
($34.43M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($24.14M)
Aug 10, 2020